Video

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic castration-resistant prostate cancer

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe